Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

RAReema AnjumUAUmmul AsfeenBBBhaswanth Bollu

Discussion

Loading...

Member takes

Overview

Systematic review reveals that anti-BCMA CAR T-cell therapy improves response rates in relapsed/refractory multiple myeloma but highlights risks of bias and limited progression-free survival.

Key Points

  • Response rates improve with anti-BCMA CAR T-cell therapy, but progression-free survival remains limited in this high-risk population.
  • Clinical outcomes analyzed across seven studies indicate a significant correlation between extramedullary disease and poor prognosis.
  • Evaluation of the risk of bias suggests potential discrepancies in treatment effects and outcome reporting among different constructs.
  • Emerging dual-targeted strategies may offer better response rates and reduce the adverse effects related to CRS in relapsed/refractory multiple myeloma.

Cite This Study

Anjum et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc19https://doi.org/10.1182/blood-2025-7608
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  2. 2Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies2025 · 11 citations
  3. 3Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy2025 · 3 citations
  4. 4Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy2025
  5. 5High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma.2025